Inhibrx Biosciences posted a reduced net loss for Q3 2025 as it continued clinical development efforts without generating revenue.

Inhibrx Biosciences reported a net loss of $43.9 million for Q3 2024, compared to a net loss of $51.8 million for Q3 2023. As of September 30, 2024, the company had cash and cash equivalents of $196.3 million.

Inhibrx Biosciences reported a net income of $1.9 billion for the second quarter of 2024, driven by gains from the separation and distribution transaction. Cash and cash equivalents totaled $226.9 million as of June 30, 2024. Research and development expenses increased to $67.6 million, while general and administrative expenses rose to $93.4 million.